| Preventing Cytomegalovirus (CMV) Organ Damage With Valganciclovir in People With HIV (NCT00006145) | National Institute of Allergy and Infectious Diseases (NIAID) | 2000-08-01 |
| Recombinant CMV gB Vaccine in Postpartum Women (NCT00125502) | Robert Pass, MD | 1999-08-01 |
| Cytomegalovirus Spread and Reactivation in Blood Cells (NCT00006314) | National Heart, Lung, and Blood Institute (NHLBI) | 1999-07-01 |
| Effects of Hormone Therapy on the Immune Systems of Postmenopausal Women With Chronic Infections (NCT00001890) | National Heart, Lung, and Blood Institute (NHLBI) | 1999-05-01 |
| Infection and Cardiovascular Disease (NCT00005547) | National Heart, Lung, and Blood Institute (NHLBI) | 1999-04-01 |
| Inflammation, Infection, and Future Cardiovascular Risk (NCT00005496) | National Heart, Lung, and Blood Institute (NHLBI) | 1998-09-01 |
| Potential Role of CMV in Restenosis Following Angioplasty, in Atherosclerosis, and in Endothelial Dysfunction (NCT00001531) | National Heart, Lung, and Blood Institute (NHLBI) | 1996-06-01 |
| Phase I/II Study of Human Anti-Cytomegalovirus (CMV) Monoclonal Antibody MSL-109 in Newborns With Symptomatic Congenital CMV Infection Without Central Nervous System Disease (NCT00004642) | National Center for Research Resources (NCRR) | 1995-02-01 |
| Viral Activation Transfusion Study (VATS) (NCT00000593) | National Heart, Lung, and Blood Institute (NHLBI) | 1994-11-01 |
| Phase III Randomized, Controlled Study of Ganciclovir for Symptomatic Congenital Cytomegalovirus Infection (NCT00004278) | National Center for Research Resources (NCRR) | 1991-12-01 |
| Prospective Study of HIV Infection in Hemophiliacs (NCT00005309) | Bloodworks | 1990-07-01 |
| Pediatric Pulmonary and Cardiovascular Complications of Vertically Transmitted HIV Infection (P2C2) (NCT00005274) | National Heart, Lung, and Blood Institute (NHLBI) | 1989-05-01 |
| Transfusion-Transmitted Cytomegalovirus Prevention in Neonates (NCT00000584) | National Heart, Lung, and Blood Institute (NHLBI) | 1983-07-01 |
| A Multiple Dose Crossover Pharmacokinetics Study to Evaluate the Effects of Food on the Absorption of Oral Ganciclovir (NCT00002251) | Hoffmann-La Roche | |
| A Study of Cidofovir in HIV-Infected Children With Cytomegalovirus (CMV) Disease (NCT00000881) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| A Randomized, Phase I/II Trial to Assess the Safety and Antiviral Effects of Escalating Doses of A Human Anti-Cytomegalovirus Monoclonal Antibody (SDZ MSL-109) in Patients With the Acquired Immunodeficiency Syndrome and CMV Viremia and/or Viruria (NCT00002268) | Sandoz | |
| A Study of HIV and Cytomegalovirus (CMV) in HIV-Infected Patients (NCT00001089) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| Open Label Ganciclovir Therapy for Sight- or Life-Threatening Cytomegalovirus Disease in the Immunocompromised Patient (NCT00002025) | Hoffmann-La Roche | |
| A Study of Lobucavir in Patients With AIDS (NCT00002352) | Bristol-Myers Squibb | |
| The Safety and Effectiveness of Different Dose Levels of 1263W94 in the Treatment of Cytomegalovirus (CMV) of the Eyes in HIV-Infected Patients (NCT00002373) | Glaxo Wellcome | |
| Kinetics of Response of Cytomegalovirus With Ganciclovir Treatment Using Quantitative Real-Time PCR (NCT00004573) | National Center for Research Resources (NCRR) | |
| The Safety and Effectiveness of FIAC in the Treatment of Cytomegalovirus (CMV) in Patients With AIDS (NCT00000981) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| A Comparison of HIV-Infected Patients With and Without Opportunistic (AIDS-Related) Infection (NCT00005572) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| Safety and Efficacy of Intravenous Magnesium Sulfate in Modulating Changes in Symptoms and Divalent Cation Levels Associated With Foscavir Therapy: A Phase IV Randomized, Double-Blind, Placebo-Controlled, Cross-Over, Pilot Study (NCT00002146) | Astra USA | |
| A Pharmacokinetic and Tolerance Study of Oral Ganciclovir in HIV-Infected Children With Asymptomatic Cytomegalovirus Infection and Low CD4 Cell Counts or Quiescent Cytomegalovirus Disease (NCT00000805) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| A Randomized, Double-Blind Study of the Efficacy and Safety of Oral Ganciclovir for the Prevention of CMV Disease in People Infected With the Human Immunodeficiency Virus (NCT00002095) | Hoffmann-La Roche | |
| A Phase I Pharmacokinetic Study in HIV-Positive Subjects of Oral Ganciclovir and Concomitant Antiretroviral Zidovudine and Didanosine (NCT00002096) | Hoffmann-La Roche | |
| A Study of AZT Plus Ganciclovir in Patients With AIDS and Cytomegalovirus (CMV) Infection (NCT00000995) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| A Study of Valacyclovir Hydrochloride in the Prevention of Life-Threatening Cytomegalovirus Disease in HIV-Infected Patients (NCT00001038) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| A Phase III Study to Evaluate the Safety and Efficacy of Ganciclovir (Dihydroxypropoxymethyl Guanine [DHPG]) Treatment of Symptomatic Central Nervous System (CNS) Congenital Cytomegalovirus (CMV) Infections. (NCT00001100) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| Ganciclovir: Compassionate Use in Patients With Serious or Life-Threatening Cytomegalovirus Infections (NCT00002024) | Hoffmann-La Roche | |
| TETRAVI Expanded Access Program (NCT07104591) | Baylor College of Medicine | |